Three biotechs line up for IPOs amid market skittishness

A trio of small drug developers are queuing up to go public as the years-long open window for biotech IPOs continues to falter. Viventia Bio, developing treatments for cancer, and Kura Oncology each filed to raise $86 million, while Dutch oncology biotech Merus lined up for a $60 million debut. Meanwhile, most of the past month's biotech debutantes have priced their IPOs at significant discounts, as marketwide concerns about drug pricing and R&D success have driven down valuations across the biopharma industry. Viventia | Kura | Merus

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.